سعر كافيكلود 0.5 مجم 30 قرص مغلف 2023

Caviclude 0.5 mg film-coated tablets (entecavir), 30 count, Global Napi > GAP, Egypt.

• Chronic hepatitis B virus infection in adults with evidence of active viral replication and persistent elevations in serum aminotransferases or histologically active disease (US entecavir).Population: Adults with chronic HBVDailyMed (U.S. NLM)

• History of hypersensitivity to entecavir or any component.International label, equivalent formulation · DailyMed (U.S. NLM)

• Severe acute exacerbations of hepatitis B may occur upon discontinuation; monitor hepatic function closely for several months after stopping. Not recommended as monotherapy in HIV/HBV co-infection without HIV therapy (resistance risk). Lactic acidosis and severe hepatomegaly with steatosis reported with nucleoside analogues.International label, equivalent formulation · DailyMed (U.S. NLM)

• Drugs reducing renal function / competing for tubular secretionModerateMay increase concentrations of entecavir or the coadministered drug.DailyMed (U.S. NLM)

• US label: Antiretroviral Pregnancy Registry data insufficient to assess risk; no adverse developmental effects in animals at clinically relevant exposures. EU SmPC: not to be used in pregnancy unless clearly necessary; effective contraception advised.General active-ingredient information · DailyMed (U.S. NLM)
• US label: unknown if present in human milk (present in rat milk); weigh benefit/risk. EU SmPC: discontinue breastfeeding during treatment.General active-ingredient information · DailyMed (U.S. NLM)

• Entecavir: Guanosine nucleoside analogue; the triphosphate competes with deoxyguanosine triphosphate and inhibits HBV polymerase base priming, reverse transcription of the negative strand and positive-strand HBV DNA synthesis.